Immunome, Inc.
immunome.comWhat Do They Do?
Develops targeted cancer therapies, including an oral therapy for desmoid tumors, antibody-drug conjugates, and radioligand therapy, for cancer patients.
10-K for FY2025, filed Mar 3, 2026We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to…View ↗
We are advancing a pipeline that includes three clinical assets and three preclinical assets. Varegacestat, formerly AL102, is an…View ↗
IM-3050 (FAP Radioligand Therapy)View ↗
How Do They Make Money?
Revenue came from payments received from AbbVie under a collaboration agreement, counted over the agreement’s performance period. The agreement ended in July 2025; the company has not generated revenue from product sales.
10-K for FY2025, filed Mar 3, 2026
$6.9M
-
10-K for FY2025, filed Mar 3, 2026
$6.9M ↗
Do Revenues Turn Into Profits?
No. It lost $212.4M in FY2025.
10-K for FY2025, filed Mar 3, 2026
−$224.1MView ↗
10-K for FY2025, filed Mar 3, 2026
−$212.4MView ↗
10-K for FY2025, filed Mar 3, 2026
−$200.6MView ↗
How Are They Changing?
From discovery platform to oncology pipeline
The older report centers on a memory B-cell platform for discovering antibody-target pairs, with programs in oncology and infectious disease. The latest report centers on a pipeline of targeted oncology therapies, including antibody-drug conjugates and other cancer treatments.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 3, 2026We are a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to…View ↗
Our primary focus area is oncology. Despite many elements that distinguish oncology from other diseases, the breadth of our platform has…View ↗
In the area of infectious diseases, we have advanced a product consisting of a cocktail of three antibodies (IMM-BCP-01) that bind and…View ↗
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to…View ↗
We are advancing a pipeline that includes three clinical assets and three preclinical assets. Varegacestat, formerly AL102, is an…View ↗
Our pipeline also includes numerous early-stage ADCs produced by our internal discovery efforts, providing opportunities for additional IND…View ↗
Who Do They Compete With?
Competes with Merck and CStone Pharmaceuticals
10-K for FY2025, filed Mar 3, 2026High or moderate expression of ROR1 has been demonstrated in a variety of hematopoietic malignancies, particularly in B-cell lymphomas, and…View ↗
Loading...
